Published on 19 Apr 2024 on Zacks via Yahoo Finance
Vertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug
Vertex Pharmaceuticals Incorporated VRTX announced that the FDA has granted a rolling new drug application (NDA) submission for suzetrigine (formerly known as VX-548) in moderate-to-severe acute pain. The company has already initiated the rolling submission process and is on track to complete the NDA submission in the second quarter of 2024.
Suzetrigine is an investigational orally administered selective NaV1.8 pain signal inhibitor. The rolling NDA submission is supported by encouraging results from the company’s phase III program for suzetrigine in acute pain management.